IA Trial Radar | ||
|---|---|---|
L'essai clinique NCT05934487 pour Insuffisance cardiaque classe II NYHA, Insuffisance cardiaque classe III NYHA, Insuffisance cardiaque est en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici. | ||
Un essai clinique correspond aux filtres sélectionnés
Vue en carte
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'essai' pour voir et discuter des informations sur l'essai dans la langue sélectionnée.
L'étude clinique NCT05934487 est un essai interventionnel pour Insuffisance cardiaque classe II NYHA, Insuffisance cardiaque classe III NYHA, Insuffisance cardiaque. Son statut actuel est : en recrutement. L'étude a débuté le 29 novembre 2023 et vise à recruter 1 750 participants. Dirigé par Endotronix, Inc., l'essai devrait être terminé d'ici le 1 septembre 2033. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 18 novembre 2025.
Résumé succinct
This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial).
The study contains of 5 arms:
NYHA II Cohort - To demonstrate safety and efficacy of the Cordella PA Sensor System in NYHA Class II HF patients, where patients have daily access to PAP data.
- Treatment Arm (Group 1)
- Active Control Arm (Group 2)
- Crossover Arm (Group 3)
NYHA III Cohort - To demonstrate safety and efficacy of the Cordella PA Sensor System in NYHA Class III HF patients, where patients have daily access to PAP data, including a randomized sub-study to evaluate a clinician-directed patient self-management strategy.
Titre officiel
A Prospective, Multi-Center, Open Label, Randomized Control Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Pulmonary Artery Sensor System in New York Heart Association (NYHA) Class II-III Heart Failure Patients
Conditions
Insuffisance cardiaque classe II NYHAInsuffisance cardiaque classe III NYHAInsuffisance cardiaqueAutres identifiants de l'essai
- ETX-HFS-PA-04
Numéro NCT
Date de début (réel)
2023-11-29
Dernière mise à jour publiée
2025-11-18
Date de fin (estimée)
2033-09
Inscription (estimée)
1 750
Type d'essai
Interventionnel
PHASE
N/A
Statut
En recrutement
Mots clés
Heart Failure
Heart Disease
Cardiovascular Disease
Pulmonary Artery Pressure
Heart Disease
Cardiovascular Disease
Pulmonary Artery Pressure
Objectif principal
Diagnostic
Plan d'attribution
Randomisé
Modèle d'intervention
Parallèle
Masquage
Double aveugle
Bras / Interventions
| Groupe de participants/Bras | Intervention/Traitement |
|---|---|
ExpérimentalNYHA II Treatment Arm All subjects will receive the Cordella Sensor.
Clinicians will manage the subjects to target PAP per protocols specific Treatment Guidelines and according to Guideline-Directed Medical Therapy. | Cordella™ Pulmonary Artery Sensor System The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management, with the goal of reducing heart failure hospitalizations. The system comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.
Cordella Sensor Cordella Delivery System myCordella Patient Reader Reader Dock Cordella Calibration Equipment (CalEQ) myCordella Tablet Cordella Data Analysis Platform (CDAP) |
ExpérimentalNYHA II Active Control Arm All subjects will receive the Cordella Sensor.
Clinicians will manage subjects using the subjects daily data trends (BP, weight, HR, SpO2 symptoms) according to Guideline Directed Medical Therapy. Once the primary endpoint (24 months) is met, subjects and clinicians will be unblinded to PAP. | Cordella™ Pulmonary Artery Sensor System The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management, with the goal of reducing heart failure hospitalizations. The system comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.
Cordella Sensor Cordella Delivery System myCordella Patient Reader Reader Dock Cordella Calibration Equipment (CalEQ) myCordella Tablet Cordella Data Analysis Platform (CDAP) |
ExpérimentalNYHA II Crossover Arm All subjects will receive the Cordella Sensor.
At least 12 months following implant and following an adjudicated HFH, subjects in the Active Control Arm can qualify to crossover to the Crossover Arm and both patients and clinicians would then be unmasked to PAP. Clinicians will then manage the subjects to target PAP per protocols specific Treatment Guidelines and according to Guideline-Directed Medical Therapy. | Cordella™ Pulmonary Artery Sensor System The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management, with the goal of reducing heart failure hospitalizations. The system comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.
Cordella Sensor Cordella Delivery System myCordella Patient Reader Reader Dock Cordella Calibration Equipment (CalEQ) myCordella Tablet Cordella Data Analysis Platform (CDAP) |
ExpérimentalNYHA III Phase I Treatment Arm All subjects will receive the Cordella Sensor.
Clinicians will manage the subjects to target PAP per protocols specific Treatment Guidelines and according to Guideline-Directed Medical Therapy. | Cordella™ Pulmonary Artery Sensor System The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management, with the goal of reducing heart failure hospitalizations. The system comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.
Cordella Sensor Cordella Delivery System myCordella Patient Reader Reader Dock Cordella Calibration Equipment (CalEQ) myCordella Tablet Cordella Data Analysis Platform (CDAP) |
ExpérimentalNYHA III Phase I Active Control Arm All subjects will receive the Cordella Sensor.
Clinicians will manage subjects using the subjects daily data trends (BP, weight, HR, SpO2 symptoms) according to Guideline Directed Medical Therapy. Once the primary endpoint (6 months) is met, subjects and clinicians will be unblinded to PAP. | Cordella™ Pulmonary Artery Sensor System The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management, with the goal of reducing heart failure hospitalizations. The system comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.
Cordella Sensor Cordella Delivery System myCordella Patient Reader Reader Dock Cordella Calibration Equipment (CalEQ) myCordella Tablet Cordella Data Analysis Platform (CDAP) |
ExpérimentalNYHA III Clinician-Directed Patient Self-Management Arm (randomized) This is Phase II / Randomization #2 following implant provided patient meets eligiibity criteria.
Subjects will be instructed to take their PAP measurements daily in addition to their weight, BP, SpO2, and HR. All data, including PAP, will be visible to the patient. Subjects will manage their diuretics per protocol specific Clinician-Directed Patient Self-Management Treatment Guidelines. Clinicians will oversee the patient self-management to target PAP per protocol specific Treatment Guidelines and according to Guideline-Directed Medical Therapy. | Cordella™ Pulmonary Artery Sensor System The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management, with the goal of reducing heart failure hospitalizations. The system comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.
Cordella Sensor Cordella Delivery System myCordella Patient Reader Reader Dock Cordella Calibration Equipment (CalEQ) myCordella Tablet Cordella Data Analysis Platform (CDAP) |
ExpérimentalNYHA III Clinician Management Arm (randomized) This is Phase II / Randomization #2 following implant provided patient meets eligiibity criteria.
Subjects will be instructed to take their PAP measurements daily in addition to their weight, BP, SpO2, and HR. All data, including PAP, will be visible to the patient. Subjects will manage their diuretics per protocol specific Clinician-Directed Patient Self-Management Treatment Guidelines. Clinicians will manage the patients to target PAP per protocols specific to Treatment Guidelines and according to Guideline Directed Medical Therapy. | Cordella™ Pulmonary Artery Sensor System The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management, with the goal of reducing heart failure hospitalizations. The system comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.
Cordella Sensor Cordella Delivery System myCordella Patient Reader Reader Dock Cordella Calibration Equipment (CalEQ) myCordella Tablet Cordella Data Analysis Platform (CDAP) |
ExpérimentalNYHA III Clinician Management Arm (Not randomized) Subject will not be randomized if they do not meet eligibility criteria to potentially be randomized to Clinician-Directed Patient Self-Management.
Subjects will be instructed to take their PAP measurements daily in addition to their weight, BP, SpO2, and HR. All data, including PAP, will be visible to the patient. Subjects will manage their diuretics per protocol specific Clinician-Directed Patient Self-Management Treatment Guidelines. Clinicians will manage the patients to target PAP per protocols specific to Treatment Guidelines and according to Guideline Directed Medical Therapy. | Cordella™ Pulmonary Artery Sensor System The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management, with the goal of reducing heart failure hospitalizations. The system comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.
Cordella Sensor Cordella Delivery System myCordella Patient Reader Reader Dock Cordella Calibration Equipment (CalEQ) myCordella Tablet Cordella Data Analysis Platform (CDAP) |
Critère principal d'évaluation
Critère secondaire d'évaluation
| Critères d'évaluation | Description de critères | Période |
|---|---|---|
Efficacy- NYHA II Cohort - A composite of first HF event or death from Cardiovascular Death up to 24 months. | A composite endpoint of first HF event or death from CVD up to 24 months. | 24 months |
Efficacy- NYHA III Cohort (Phase I) - a composite of HF events or death from cardiovascular disease at 6 months | A composite of HF events or death from cardiovascular disease at 6 months | 12 months |
Safety- Randomized Arm- Freedom from device/system related complication | Freedom from device/system related complication at 24 months | 24 months |
Safety- Randomized Arm-Freedom from pressure sensor failure | Freedom from pressure sensor failure at 24 months | 24 months |
Safety- Single Arm-Freedom from device/system related complication | Freedom from device/system related complication at 12 months | 12 months |
Safety- Single Arm- Freedom from pressure sensor failure | Freedom from pressure sensor failure at 12 months | 12 months |
Efficacy- NYHA III Cohort (Phase II) - A test of non-inferiority at 12 months of the percentage of patients at or below trend seated mPAP of 25 mmHg in (i) Clinician-Directed Patient Self-Management vs. (ii) Clinician Management Arm | A test of non-inferiority at 12 months of the percentage of patients at or below trend seated mPAP of 25 mmHg in (i) Clinician-Directed Patient Self-Management vs. (ii) Clinician Management Arm | 12 months |
| Critères d'évaluation | Description de critères | Période |
|---|---|---|
Efficacy - NYHA II Cohort & NYHA III Cohort - HF Hospitalizations | -Incidence of HFH at 12, 18, and 24 months | 12 months, 18 months and 24 months |
Efficacy - NYHA II Cohort & NYHA III Cohort- HF Hospitalizations | -Number of HFH at 12- and 24-months post-implant compared to the number of HFH in the 12 and 24 months prior to implant | 12 months and 24 months |
Efficacy - NYHA II Cohort & NYHA III Cohort - HF Hospitalizations | Combined outcome of :
1. First and recurrent HF Hospitalizations
2. Urgent HF Visits
3. all-cause mortality | 12 month |
Efficacy - NYHA II Cohort & NYHA III Cohort - HF Hospitalizations | Length of stay | Duration of study (to 5 years) |
Efficacy - NYHA II Cohort & NYHA III Cohort - All-cause mortality | All-cause mortality | Duration of study (to 5 years) |
Efficacy - NYHA II Cohort & NYHA III Cohort - Death from cardiovascular disease | Death from cardiovascular disease | Duration of study (to 5 years) |
Efficacy - NYHA II Cohort & NYHA III Cohort - Urgent HF visits | Urgent HF visits | Duration of study (to 5 years) |
Efficacy - NYHA II Cohort - Incidence of HF hospitalizations or all-cause mortality | Incidence of HF hospitalizations or all-cause mortality | 12 months |
Efficacy - NYHA III Cohort - Composite of first HF event (HF hospitalization or urgent HF visit or death from cardiovascular disease (CVD) | Composite of first HF event (HF hospitalization or urgent HF visit or | Up to 24 months |
Eff-NYHA II Cohort & NYHA III Cohort -time to death, # HFH or urgent HF visits, time to first HFH or urgent HF visit, diff >/= 15 KCCQ BSL to 24 mos,diff >/= 10 in KCCQ BSL to 24 mos, diff >/= 5 in KCCQ BSL to 24 mos, diff >/= 30m in 6 MWT BSL to 24 mos | -time to death, # HFH or urgent HF visits, time to first HFH or urgent HF visit, diff \>/= 15 KCCQ BSL to 24 mos,diff \>/= 10 in KCCQ BSL to 24 mos, diff \>/= 5 in KCCQ BSL to 24 mos, diff \>/= 30m in 6 MWT BSL to 24 mos | Duration of study (to 5 years) |
Efficacy - NYHA II Cohort & NYHA III Cohort - Various measurements via ECHO and evaluated by ECHO core lab at Baseline, 12, 24, 36, 48 and 60 months. | Various measurements via ECHO and evaluated by ECHO core lab at Baseline, 12, 24, 36, 48 and 60 months. | Duration of study (to 5 years) |
Efficacy - NYHA II Cohort & NYHA III Cohort - Heart failure related medication changes | Heart failure related medication changes | Duration of study (to 5 years) |
Efficacy - NYHA II Cohort & NYHA III Cohort - Change in PAP from baseline | Change in PAP from baseline | Duration of study (to 5 years) |
Efficacy - NYHA II Cohort & NYHA III Cohort - Change in PAP from baseline as measured by echocardiogram (ECHO) and evaluated by anECHO core lab at 12, 24, 36, 48, and 60 months | Change in PAP from baseline as measured by echocardiogram (ECHO) and evaluated by an ECHO core lab at 12, 24, 36, 48, and 60 months | Duration of study (to 5 years) |
Efficacy - NYHA II Cohort & NYHA III Cohort - Patient Outcome Measures as measured by KCCQ, Brief Illness Perception Questionnaire, andEuroQol-5 Dimensions-5 Level (EQ-5D-5L) | Patient Outcome Measures as measured by KCCQ, Brief Illness Perception Questionnaire, and EuroQol-5 Dimensions-5 Level (EQ-5D-5L) | Duration of study (to 5 years) |
Efficacy - NYHA II Cohort & NYHA III Cohort - Functional status improvement as measured by NYHA classification and 6MWT | Functional status improvement as measured by NYHA classification and 6MWT | Duration of study (to 5 years) |
Efficacy - NYHA II Cohort & NYHA III Cohort - HFH stratified by ejection fraction (HFrEF, HFmrEF, HFpEF, and HF recovered EF) and baselineenrollment ECHO estimated systolic PAP | HFH stratified by ejection fraction (HFrEF, | Duration of study (to 5 years) |
Efficacy - NYHA II Cohort & NYHA III Cohort - Mortality by baseline EF (HFrEF, HFmrEF, HFpEF, HF recovered EF), and baseline enrollmentECHO estimated systolic PAP | Mortality by baseline EF (HFrEF, HFmrEF, | Duration of study (to 5 years) |
Efficacy - NYHA II Cohort & NYHA III Cohort - Days alive outside hospital (DAOH) | Days alive outside hospital (DAOH) | Duration of study (to 5 years) |
Efficacy - NYHA II Cohort & NYHA III Cohort - Health Economic Analysis | Health Economic Analysis | Duration of study (to 5 years) |
Efficacy - NYHA II Cohort & NYHA III Cohort - Adherence to regular PAP and vital sign measurements including a sub-analysis on subjectswho move to another area of the country | Adherence to regular PAP and vital sign measurements including a sub-analysis on subjects who move to another area of the country | Duration of study (to 5 years) |
Safety - NYHA II Cohort - Freedom from device/system related complications at 12 months | Freedom from device/system related complications at 12 months | Duration of study (to 5 years) |
Safety - NYHA III Cohort - Freedom from pressure sensor failure at 12 months | Freedom from pressure sensor failure at 12 months | Duration of study (to 5 years) |
Safety - NYHA II Cohort & NYHA III Cohort - Pressure sensor failure rate throughout the study | Pressure sensor failure rate throughout the study | Duration of study (to 5 years) |
Safety - NYHA II Cohort & NYHA III Cohort - Frequency of serious adverse events throughout the study | Frequency of serious adverse events throughout the study | Duration of study (to 5 years) |
Safety - NYHA II Cohort & NYHA III Cohort - Frequency of implant procedure and procedure related adverse events and serious adverse events | Frequency of implant procedure and procedure related adverse events and serious adverse events | Duration of study (to 5 years) |
Safety - NYHA III Cohort - Freedom from device/system related complications at 24 months | Freedom from device/system related complications at 24 months | Duration of study (to 5 years) |
Safety - NYHA III Cohort - Freedom from pressure sensor failure at 24 months | Freedom from pressure sensor failure at 24 months | Duration of study (to 5 years) |
Critères d'éligibilité
Âges éligibles
Adulte, Adulte âgé
Âge minimum
18 Years
Sexes éligibles
Tous
4. Subjects should be receiving appropriate medical therapy for heart failure according to current AHA/ACC guidelines as standard-of-care for HF therapy in the United States, or current ESC guidelines for HF treatment in Europe for at least 30 days prior to the Screening/Enrollment visit. Stable is defined as no more than a 100% increase or 50% decrease in dose. These criteria may be waived if a subject is intolerant of ACE-I, ARB, ARNI), MRA, beta-blockers, or SGLT2i, subject is unable to afford these agents, subject has contraindications to these agents, or these agents are not indicated under the Guidelines. Such intolerance, lack of affordability, contraindications, or lack of indications must be documented.
HFrEF (EF < 50%): Subject has been on stable medications maximized to the subject's tolerance of ACE-I or ARB or ARNI, MRA, beta-blockers, and SGLT2i as determined by the study investigator for at least 30 days prior to Screening/Enrollment
HFpEF (EF ≥ 50%): Subject has been on stable medication maximized to the subject's tolerance of SGLT2i as determined by the study investigator for at least 30 days prior to Screening/Enrollment 5. NYHA II Cohort- HF related hospitalization within 6 months (last hospitalization should be 30 days before Screening /Enrollment) 5. NYHA III Cohort -HF related hospitalization within 12 month (last hospitalization should be 30 days before Screening/Enrollment)
6. Subjects should be on diuretic therapy (≥40 mg] furosemide or equivalent) for ≥ 1 month at time of Screening
7. Subjects who are physically able to hold the myCordella™ Patient Reader unit (approximate weight 1.3lb) against the ventral thoracic surface for up to 2 minutes per day while in a seated position, as well as dock and undock the myCordella™ Patient Reader
8. Subjects with sufficient eyesight, hearing, and mental capacity to respond to the myCordella™ Patient Reader's audio/visual cues and operate the myCordella™ Patient Reader
9. Subject has sufficient Cellular and/ or Wi- Fi Internet coverage at home
10. Subject agrees to return to the treating Investigator for all scheduled follow up visits and can return to the hospital for follow up
- ACC/AHA Stage D refractory HF (including a known history of >24 hours of IV inotropic therapy to support circulation within the past 6 months (other than relation to a procedure))
- Subjects with history of recurrent pulmonary embolism (≥2 episodes within 5 years prior to Screening Visit) and/or deep vein thrombosis in the femoral or IJ vein used for access (< 3 month prior to Screening Visit)
- Subjects with a resting systolic blood pressure <90 mmHg and/ or severe pre-capillary pulmonary hypertension with a pulmonary artery systolic pressure of ≥70 mm/Hg with pulmonary capillary wedge pressure ≤ 15 mmHg at the Cordella PA Sensor Implant RHC (V2)
- Subjects who have had a major cardiovascular (CV) event (e.g., myocardial infarction, stroke) within 3 months of the Screening Visit
- Unrepaired severe valvular disease
- Subjects with significant congenital heart disease that has not been repaired and would prevent implantation of the Cordella PA Sensor or mechanical/tissue right heart valve(s)
- Subjects with known coagulation disorders
- Subjects with a hypersensitivity or allergy to platelet aggregation inhibitors including aspirin, clopidogrel, prasugrel, and ticagrelor; or patients unable to take dual antiplatelet or anticoagulants for one-month post implant
- Known history of life-threatening allergy to contrast dye.
- Subjects whereby RHC is contraindicated
- Subjects with an active infection at the Cordella Sensor Implant Visit
- Subjects with a GFR <20 ml/min or who are on chronic renal dialysis
- Implanted with Cardiac Resynchronization Therapy-Pacemaker (CRT-P) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D), or having undergone mitral/tricuspid valve repair/replacement within 90 days or catheter ablation for atrial fibrillation within 30 days prior to screening visit
- Received or are likely to receive an advanced therapy (e.g., durable mechanical circulatory support or lung or heart transplant) in the next 24 months
- Subjects who are pregnant or breastfeeding
- Subjects who are unwilling or deemed by the Investigator to be unwilling to comply with the study protocol, or subjects with a history of non-compliance
- Severe illness, other than heart disease, which would limit survival to <2 years
- Subjects whose clinical condition, in the opinion of the Investigator, makes them an unsuitable candidate for the study
- Subjects enrolled in another investigational trial with an active Treatment Arm
- Subject who is in custody by order of an authority or a court of law
Endotronix, Inc.Contact central de l'essai
Contact: Andrea Sauerland, (630) 473-3200, [email protected]
49 Centres de l'essai dans 3 pays
Aalst
AZORG Aalst, Aalst, Aalst, 9300, Belgium
Kathy de Knijf, Contact, +32 53 76 41 11, [email protected]
Jozef Bartunek, Investigateur principal
En recrutement
UZ Brussel, Brussels, Belgium
Evelyne Wirix, Contact, +32 2 477 41 11, [email protected]
Frederik Verbrugge, Investigateur principal
En recrutement
Arizona
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, 85013, United States
Namit Rohant, MD, Contact
En recrutement
California
USC, Los Angeles, California, 90033, United States
Aaron Wolfson, Contact
Aaron Wolfson, Investigateur principal
En recrutement
UCSF Medical Center, San Francisco, California, 94143, United States
Mark Lacsamana, Contact
Shweta Motiwala, MD, Investigateur principal
En recrutement
Florida
Baptist Health South Florida, Miami, Florida, 33176, United States
Kenia Capdevilla, Contact
Sandra Chaparro, MD, Investigateur principal
En recrutement
Ascension Sacred Heart, Pensacola, Florida, 32504, United States
Walid Kara, Contact
Rohit Amin, Investigateur principal
En recrutement
Georgia
Piedmont, Atlanta, Georgia, 30309, United States
Gigi Davis, RN, Contact
Kent Nilsson, Investigateur principal
En recrutement
Illinois
Advocate Health System, Downers Grove, Illinois, 60515, United States
Actif, pas en recrutement
Heart Care Centers of Illinois (HCCI), Palos Park, Illinois, 60464, United States
Jessica Kwak, Contact
Chirag Rajyaguru, Investigateur principal
En recrutement
Indiana
Ascension St. Vincent's, Indianapolis, Indiana, 46260, United States
Taylor Gilliam, Contact
Ashwin Ravichandran, Investigateur principal
En recrutement
Kansas
University of Kansas Medical Center (KUMC), Kansas City, Kansas, 66160, United States
Yolanda Murr, Contact
Hirak Shah, MD, Investigateur principal
En recrutement
Maryland
University of Maryland, Baltimore, Maryland, 21201, United States
Actif, pas en recrutement
MedStar, Baltimore, Maryland, 21239, United States
Rebecca Comaty, Contact
Erika Feller, Investigateur principal
En recrutement
Massachusetts
Tufts Medical Center, Boston, Massachusetts, 02111, United States
Gaurav Das, Contact
Michael Kiernan, MD, Investigateur principal
En recrutement
Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, 02215, United States
Actif, pas en recrutement
Michigan
Ascension Providence Hospital Cardiology - Heart Cardiology, Howell, Michigan, 48843, United States
Yulia Abidov, Contact
Marcel Zughaib, MD, Investigateur principal
En recrutement
Minnesota
Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, 55407, United States
Actif, pas en recrutement
University of Minnesota, Minneapolis, Minnesota, 55455, United States
Julie Dicken, Contact
Tamas Alexy, MD, Investigateur principal
En recrutement
Centra Care Heart Center, Saint Cloud, Minnesota, 56303, United States
Nathan Warnert, Contact
Jamie Pelzel, MD, Investigateur principal
En recrutement
Missouri
St. Lukes/ Mid-American Heart Institute, Kansas City, Missouri, 64111, United States
Amanda Huffman, Contact
Michael Nassif, MD, Investigateur principal
En recrutement
Washington University, St Louis, Missouri, 63110, United States
Jean Flanagan, Contact
Justin Vader, MD, Investigateur principal
En recrutement
New York
Mount Sinai West, New York, New York, 10019, United States
Sajiny John, Contact
Johanna Contreras, MD, Investigateur principal
En recrutement
Mount Sinai, New York, New York, 10029, United States
Noah Moss, Contact
Noah Moss, MD, Investigateur principal
En recrutement
Lenox Hill/ Northwell Health, New York, New York, 10075, United States
Virgenmina (Angie) Lugaro, Contact
Sirish Vullaganti, MD, Investigateur principal
En recrutement
Stony Brook University Med Center, Stony Brook, New York, 11794, United States
Indre Caikauskaite, Contact
Hal Skopicki, MD, Investigateur principal
En recrutement
North Carolina
Duke University, Durham, North Carolina, 27710, United States
Marat Fudim, MD, Investigateur principal
En recrutement
Ohio
The Christ Hospital- Cincinnati, Cincinnati, Ohio, 45219, United States
Actif, pas en recrutement
University of Cincinnati, Cincinnati, Ohio, 45267, United States
Harshada More, Contact
Vlad Cotarlan, MD, Investigateur principal
En recrutement
University Hospital (Cleveland), Cleveland, Ohio, 44106, United States
Monique Robinson, MD, Contact
Monique Robinson, MD, Investigateur principal
En recrutement
Oregon
Providence St. Vincent's - Portland, Portland, Oregon, 97225, United States
Dr. Vidang Nguyen, MD, Contact, [email protected]
Vidang Nguyen, Investigateur principal
En recrutement
Oregon Health Science Portland, Portland, Oregon, 97239, United States
Actif, pas en recrutement
Pennsylvania
Penn State Health, Hershey, Pennsylvania, 17033, United States
Actif, pas en recrutement
UPMC, Pittsburgh, Pennsylvania, 15213, United States
Actif, pas en recrutement
South Carolina
PRISMA Health- Upstate, Greenville, South Carolina, 29605, United States
Actif, pas en recrutement
South Dakota
Sanford, Sioux Falls, South Dakota, 57105, United States
Diana Ibarra-Garcia, Contact
Marian Petrasko, MD, Investigateur principal
En recrutement
Tennessee
Vanderbilt, Nashville, Tennessee, 37232, United States
Jaime Rich, Contact
Sandip Zalawadiya, MD, Investigateur principal
En recrutement
Texas
Austin Heart, Austin, Texas, 78756, United States
Actif, pas en recrutement
Medical City Healthcare Dallas, Dallas, Texas, 75240, United States
Mona Hedra, Contact
Claudius Mahr, MD, Investigateur principal
En recrutement
Baylor Scott & White -Dallas, Fort Worth, Texas, 76110, United States
Cesar Guerrero, MD, Contact
Cesar Guerrero, MD, Investigateur principal
En recrutement
Baylor/Texas Heart, Houston, Texas, 77030, United States
Actif, pas en recrutement
Methodist San Antonio, San Antonio, Texas, 78229, United States
Marina Martin, Contact
Chandra Kunavarapu, Investigateur principal
En recrutement
Baylor - Temple, Temple, Texas, 76508, United States
Amy Watts, Contact
Jaime Hernandez, MD, Investigateur principal
En recrutement
Vermont
University of Vermont, Burlington, Vermont, 05401, United States
Actif, pas en recrutement
Washington
Providence Everett, Everett, Washington, 98201, United States
Becca Watson, Contact
Feng Wang, MD, Investigateur principal
En recrutement
West Virginia
West Virginia University, Morgantown, West Virginia, 26506, United States
Actif, pas en recrutement
Wisconsin
University of Wisconsin, Madison, Wisconsin, 53792, United States
Karen Olson, Contact
Peter Marogil, MD, Investigateur principal
En recrutement
Advocate Aurora St. Luke's, Milwaukee, Wisconsin, 53215, United States
Actif, pas en recrutement
University Hospital Galway, Galway, Ireland
Eileen Coen, Contact, +353 91 524 222, [email protected]
Faisal Sharif, Investigateur principal
En recrutement